Kenta Biotech Ltd
Kenta Biotech AG is a biotech company focused on the discovery and development of fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in hospital settings. Their mission is to develop fully human monoclonal antibodies for adjunctive treatment of severe hospital-acquired infections, leveraging their MabIgX® technology to generate highly effective therapeutic antibodies. The company emphasizes innovation in addressing major problems like hospital-acquired infections, especially in ICU environments, and aims to improve patient outcomes through antibody-based therapies.
Industries
Nr. of Employees
small (1-50)
Kenta Biotech Ltd
14009 NW Harbor Ln, Portland, OR 97229, USA
Products
Research reagent and assay kit catalog
Broad catalog of research reagents and consumables for molecular biology and immunology research, including ELISA test kits, monoclonal and polyclonal antibodies, recombinant proteins, plasmids, cell lines, buffers, and particle reagents.
Research reagent and assay kit catalog
Broad catalog of research reagents and consumables for molecular biology and immunology research, including ELISA test kits, monoclonal and polyclonal antibodies, recombinant proteins, plasmids, cell lines, buffers, and particle reagents.
Services
Scheduled demo unit installation and user training for point‑of‑care/demo equipment (example: 30‑day demo unit with defined test capacity), delivered via appointment.
Scheduled demo unit installation and user training for point‑of‑care/demo equipment (example: 30‑day demo unit with defined test capacity), delivered via appointment.
Expertise Areas
- Monoclonal antibody discovery
- Translational and preclinical development
- Infectious disease therapeutics (nosocomial infections, RSV)
- Immunoassay development and neutralization testing
Key Technologies
- Fully human monoclonal antibody generation platform
- In vitro neutralization assays
- ELISA and immunoassays
- Recombinant protein production